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Abstract: The majority of colorectal cancers are induced by subsequent mutations in APC and
KRAS genes leading to aberrant activation of both canonical WNT and RAS signaling. However,
due to induction of feedback rescue mechanisms some cancers do not respond well to targeted
inhibitor treatments. In this study we show that the APC and KRAS mutant human colorectal
cancer cell line HCT-15 induces canonical WNT signaling through YAP in a MEK dependent
mechanism. This inductive loop is disrupted with combined tankyrase (TNKS) and MEK inhibition.
RNA sequencing analysis suggests that combined TNKS/MEK inhibition induces metabolic stress
responses in HCT-15 cells promoting a positive FOXO3/FOXM1 ratio to reduce antioxidative and
cryoprotective systems.
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1. Introduction
Colorectal cancer is the second leading cause of cancer death worldwide (WHO, [1]). About 90%
of colorectal cancers (CRCs) are induced by loss-of-function mutations in the adenomatous polyposis
coli (APC) tumor suppressor gene, followed by nuclear accumulation of the canonical WNT signaling
effector β-catenin [2]. Subsequent onset of adenoma progression is induced by a secondary oncogenic
KRAS mutation in 50% of colorectal cancers [3–5]. Neither APC nor KRAS mutations alone induce
a colorectal cancer phenotype [6], although APC mutations also induce RAS activation through
inactivation of glycogen synthase kinase 3β (GSK3β) [7]. The GSK3β containing β-catenin destruction
complex is stabilized by both APC and axis inhibition protein 1 and 2 (AXIN1/2) in the absence of
canonical WNT signals, promoting proteasomal degradation of both β-catenin (reviewed by [8]) and
a subset of RAS proteins [7]. Tankyrase (TNKS) is a central cytoplasmic regulator of the WNT/β-catenin
signaling pathway which marks AXIN1/2 for degradation through ADP-ribosylation, and thereby
prevents degradation of β-catenin [9,10]. Development of TNKS inhibitors has therefore gained
increasing attention as a treatment strategy for WNT induced colorectal cancer.
Due to the extensive crosstalk between major signaling pathways, pathway inhibition in cancer
cells commonly experience upregulation of feedback rescue mechanisms in order to survive and
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maintain their original cell growth potential. The hippo signaling pathway effector YES-associated
protein (YAP) has been found to promote resistance to MEK and RAF inhibition in non-small cell
lung cancer [11], while TNKS activity protected lung cancer cells from Epidermal Growth Factor
Receptor (EGFR) inhibition [12]. Furthermore, MEK inhibition has been identified as a sensitizing
factor for TNKS inhibition in KRAS mutant CRCs, presumably through inhibition of a feedback rescue
mechanism involving Fibroblast Growth Factor Receptor 2 (FGFR2) [13]. Conversely, TNKS inhibition
sensitized KRAS wild type (WT) CRCs to MEK inhibition [14]. Combining TNKS and RAS/MEK/ERK
inhibition is therefore attractive strategies against colorectal cancer although induction of further
feedback rescue mechanisms may require extensive combination of inhibitor treatments in order to
fully eradicate the cancer [14].
In this study, we used the KRAS mutant HCT-15 colorectal cancer cell line as a model system to
investigate MEK inhibitor (MEKi) mediated activation of canonical WNT signaling. Taking advantage
of the highly specific tankyrase1/2 inhibitor (TNKSi) G007-LK [15], and the highly selective MEKi
GDC-0973 [16], we observed a synergistic growth reduction with combined TNKSi/MEKi treatment in
HCT-15 cells. In contrast, the APC mutant and KRAS WT COLO320DM colorectal cancer cell line did
not reduce growth or change canonical WNT activity upon treatment with the MEKi, neither alone or in
combination with the TNKSi. In order to reveal transcriptional changes that may explain both enhanced
canonical WNT signaling with MEKi treatment, and the synergistic growth reduction observed with
combined TNKSi/MEKi treatment in HCT-15 cells, we performed RNA sequencing (RNAseq) analysis.
Ingenuity pathway analysis (IPA) of RNAseq data suggested the involvement of YAP and FOXM1 in
mediating activation of canonical WNT signaling upon MEK inhibition. However, esiRNA mediated
knock down (KD) experiments showed that YAP was required for enhanced AXIN2 transcription,
while both YAP and FOXM1 reduction only moderately effected STF/Renilla activation. Furthermore,
combined TNKS/MEK inhibition induced a synergistic amount of differentially expressed genes
(DEG’s) which were associated with stress responses and cell cycle arrest, inducing a favorable
forkhead box protein O3 (FOXO3)/forkhead box protein M1 (FOXM1) ratio to prevent antioxidative
and cryoprotective systems.
2. Results
2.1. MEK Inhibition Sensitizes KRAS Mutant HCT-15 Colorectal Cancer Cells to Tankyrase Inhibition
It has previously been shown that TNKS inhibition sensitizes KRAS mutant cancer cells to growth
inhibition by MEK inhibitors [13], also in cell lines whose proliferation rate is unaffected by single
TNKS inhibitor treatment [14]. To explore the underlying mechanism mediating this effect we initially
investigated cell growth in COLO320DM (APC mutated/KRAS WT) and HCT-15 (APC mutated/KRAS
mutated) colorectal cancer cells under the influence of 1 µM G007-LK (TNKS inhibitor; TNKSi) and/or
1 µM GDC-0973 (MEK inhibitor; MEKi). The biotarget specific responses of TNKSi and MEKi treatments
were confirmed by western blot (WB) analysis of TNKS1/2 and phosphorylated MEK1/2 protein levels
(Figure S1A,B).
TNKS inhibition significantly reduced cell growth by 53% in COLO320DM cells compared
to the DMSO control (Figure 1A and Figure S2A), while HCT-15 cells were unaffected (Figure 1B
and Figure S2B). MEKi treatment did not significantly influence cell growth in COLO320DM,
while in HCT-15 cells MEK inhibition led to a moderate and significant 11% growth reduction.
Combined TNKSi/MEKi treatment resulted in similar cell growth effects as single TNKSi treatment in
COLO320DM, while in HCT-15 cells the combination synergistically reduced cell growth by 56%.
CyclinD1 (CCND1) is required for the cell cycle G1/S transition [17,18], and the transcription
level of CCND1 was investigated after 24 h incubation with inhibitors. In COLO320DM cells CCND1
transcription was only affected by TNKS inhibition, following the response pattern in cell growth
reduction (Figure 1C). In HCT-15 cells, CCND1 transcription was significantly reduced by both single
and combined TNKS and MEK inhibition (Figure 1D), despite no or minor effects on cell growth
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with single inhibitor treatments. The inconsistency between CCND1 transcription and cell growth
with single inhibitor treatments in HCT-15 cells indicates initiation of CyclinD1 independent rescue
mechanisms to maintain normal cell growth.
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2.2. MEK Inhibition Induces Canonical WNT Signaling in HCT-15 Cells
Canonical WNT signaling is a central driver of cell proliferation, and both COLO320DM and
HCT-15 cells display increased canonical WNT activity due to mutations in the APC tumor suppressor
gene [19]. We therefore wanted to investigate whether the observed responses in cell growth upon
single and combined TNKSi/MEKi treatments could be correlated with canonical WNT signaling.
COLO320DM and HCT-15 cells stably transfected with the SuperTOP-Flash (STF) reporter gene and
control pRL-TK (Renilla) plasmid were used, and canonical WNT signaling was quantified after 24 h
of treatment with inhibitors. In parallel we also measured the transcription level of the canonical
WNT/β-catenin target gene AXIN2 [20,21]. In COLO320DM cells, TNKSi treatment both alone and in
combination with the MEKi, resulted in both reduced STF/Renilla activation (0.7 fold) and AXIN2
transcription (0.35 fold) compared to the DMSO controls (Figure 2A). In contrast, single MEKi treatment
did not influence on either STF/Renilla activity or AXIN2 mRNA levels, reflecting the observed growth
response (Figure 1A).
In HCT-15 cells, TNKSi treatment slightly reduced STF/Renilla activity (0.9 fold) and more
strongly reduced AXIN2 transcription (0.5 fold) compared to the DMSO controls (Figure 2B), despite
having no effect on cell growth (Figure 1B). However, in contrast to observations in COLO320DM cells,
MEKi treatment enhanced both STF/Renilla activity (more than 2.0 fold) and AXIN2 transcription
(1.7 fold) in HCT-15 cells. Both effects were completely counteracted with combined TNKSi/MEKi
treatment. Similar results were obtained in HCT-15 cells with a second independent MEK inhibitor
(GDC-0623), thus verifying that the activation of canonical WNT signaling was not due to unspecific
GDC-0973 inhibitor effects (Figure S3).
To gain further insight into the cellular responses of TNKS and MEK inhibitor treatments we analyzed
the nuclear and cytoplasmic protein levels of central canonical WNT signaling components in COLO320DM
and HCT-15 cells. AXIN1 is a structural protein of the cytoplasmic β-catenin destruction complex, and its
stability is directly regulated by the catalytic activity of TNKS [9,22]. WB analysis confirmed stabilization
of AXIN1 by TNKSi treatment (alone and together with MEKi) in COLO320DM cells, while single MEKi
treatment did not affect AXIN1 stability (Figure 2C). Accordingly, both nuclear and cytoplasmic levels of
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non-phosphorylated (active) β-catenin (ABC) protein were reduced by TNKSi treatment, and unaffected
by MEKi treatment.
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signaling upon inhibitor treatments Luciferase reporte assay wa condu ted on COLO320DM (A) and
HCT-15 (B) cells stably transfected with SuperTop-Flash (STF) and Renilla plasmids. AXIN2 transcription
levels were measured on untransfected cells. Relative gene transcription levels were normalized to
internal GAPDH levels. Regulations of AXIN1 and non-phospho (active) β-catenin (ABC) protein levels
were investigated by Western blot analysis in untransfected COLO320DM and HCT-15 cells (C). LaminB1
and ACTIN were used as loading control for the nuclear and cytoplasmic fraction, respectively. Numbers
above ABC blot indicate volume measurements of ABC/ACTIN band intensity, and relative to the DMSO
control. Representative graphs and immunoblots from at least 3 independent experiments are shown.
Bars in (A) and (B) indicate mean relative expression values (± STDEV) from at least 3 technical replicates.
All assays were performed after 24 h incubation with inhibitors as indicated. * p < 0.05.
In contrast, the cytoplasmic protein levels of AXIN1 were not stabilized with combined
TNKSi/MEKi treatment in HCT-15 cells, despite increased nuclear AXIN1 protein levels with both
single TNKSi and combined TNKSi/MEKi treatments. Furthermore, single TNKSi treatment did not
affect ABC levels in HCT-15 cells, while both single MEKi and combined TNKSi/MEKi treatment
slightly enhanced both nuclear and cytoplasmic levels of ABC, reflecting the absence of stabilized
AXIN1 in the cytoplasm with combined TNKSi/MEKi treatment.
Together these results imply that MEKi treatment induces activation of canonical WNT signaling
in HCT-15 cells as an escape mechanism to oppose MEK inhibition, and to maintain normal cell growth.
However, this effect is attenuated with combined TNKSi/MEKi treatment, uncoupled from AXIN1
stabilization, and reflected by synergistic cell growth reduction.
2.3. RNAseq Analysis Reveals a Positive FOXO3/FOXM1 Ratio with Combined TNKS/MEK Inhibition in
HCT-15 Cells
To better understand the global transcriptional changes induced by TNKS and MEK inhibition
in HCT-15 cells RNA sequencing (RNAseq) and RNAseq analysis was conducted. Three biological
replicates were analyzed after 24 h of treatment with DMSO control, TNKSi and/or MEKi. A principal
component analysis (PCA) of the RNAseq data displayed tight clustering of the triplicate samples
within each treatment group (Figure S4).
Differentially expressed genes (DEG’s) identified in a DESeq2 analysis were compared across
treatments using a Venn diagram. Single TNKSi treatment induced a relatively low number of 374
DEG’s (106 unique), while single MEKi treatment induced significant transcription changes in 3457
genes (246 unique) compared to the DMSO control (Figure 3A).
Combined TNKSi/MEKi treatment produced 5825 DEG’s, where 2528 of these were uniquely
regulated; clearly showing a synergistic regulatory transcriptional effect compared to single inhibitor
treatments. Expected TNKSi and MEKi effects were confirmed by investigating canonical WNT (LEF1,
SP5, TCF7L2 and CDH1) and MEK/ERK (FOXO3, ELK1, FOSL1 and FOS) downstream target gene
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transcription regulation in the RNAseq analysis (Figure 3B and Figure S5). Transcription levels of
selected genes (WNT; SP5, TCF7L2 and CDH1, MEK/ERK; FOXO3, FOSL1 and FOS) were verified
with RT-qPCR analysis on cDNAs created from the same RNA samples (Figure 3B), and RT-qPCR data
showed similar patterns as RNAseq data. Both analyses revealed reduced canonical WNT target gene
transcription upon TNKS inhibition, and enhanced transcription of the canonical WNT target genes
SP5 (transcription factor) and CDH1 (E-cadherin) with MEK inhibition. Combined TNKSi/MEKi
treatment counteracted the MEKi induced transcription of SP5, while TCF7L2 (TCF4) transcription
was induced only when the inhibitors were combined. MEK/ERK target genes were only regulated by
the MEKi, although MEK inhibition potentiated HCT-15 cells to TNKS inhibition by further reducing
MEK/ERK target gene transcription with combined TNKSi/MEKi treatment.
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Figure 3. RNAseq analysis of TNKSi and MEKi treated HCT-15 cells. RNAseq count data was analyzed
using the count-based statistical method DESeq2. A Venn diagram was created of differentially
expressed genes (DEG’s) between the inhibitor treated samples (average of triplicates) compared
to the DMSO control (> ±0.5 logfold, padj < 0.1) (A). Red numbers indicate upregulated genes,
while blue numbers indicate downregulated genes. Purple numbers indicate TNKSi regulated genes,
orange numbers indicate MEKi regulated genes, and black numbers indicate combined TNKSi/MEKi
regulated genes. The transcriptional changes in a small selection of canonical WNT (LEF1, SP5,
TCF7L1 and CDH1) and MEK/ERK (FOXO3, ELK1, FOSL1 and FOS) downstream target genes were
investigated for their response to inhibitor treatments. The transcription level of SP5, TCF7L1, CDH1,
FOXO3, FOSL1 and FOS genes were verified with RT-qPCR on cDNAs created from the same RNA
samples as the sequenced RNA (B). RT-qPCR data shows mean relative expression values (± STDEV)
from the 3 biological replicates, each with 3 technical replicates. Gene transcription levels were
normalized to internal GAPDH levels, and are shown as relative to the DMSO control. Individual
RNAseq data for the selected genes are visualized with a heatmap, and the average log2 fold changes
in gene transcription are indicated in the table below. Only log2 fold changes with a p-value < 0.05 are
shown. Heatmap Scale bar (red = high, yellow = medium and blue = low) indicates relative differences
in log2 fold change within each row.
Next, a heatmap of the 50 most regulated genes compared to the DMSO control, regardless of
inhibitor treatment, was created (Figure 4A and Tables S1 and S2). The heatmap revealed 3 distinct
groups of transcriptional regulation. One group (20 genes) was downregulated by the MEKi compared
to the DMSO control, with minor additional changes in combination with TNKS inhibition (group I).
Withi this group we obs rved the ETV4, ETV5 and MYEOV genes which h ve been shown to promote
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resistance to MAP Kinase inhibitors [23] as well as promoting cancer cell proliferation, invasion
and migration [24]. The second group consisting of 22 genes (group II) was mildly upregulated
by single TNKS and MEK inhibition, with additive effects with combined TNKSi/MEKi treatment.
Among these genes we observed CLIC3, PRAP1 and AHNAK2, which have been shown to promote
cancer progression of gallbladder carcinoma [25], chemotherapeutic drug resistance in colorectal
cancer [26] and epithelial to mesenchymal transition in clear cell renal cell carcinoma [27], respectively.
The third group (goup III) consists of 7 genes which were upregulated by the MEKi, and with minor
changes by the TNKSi. Ingenuity pathway analysis (IPA) software was used to investigate canonical
pathways affected by genes in group I and III (mostly affected by the MEKi).
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control was created (A). 3 distinct groups of reg lations were revealed. One group (I) consisting of
20 genes was mainly do nregulate by the MEKi, with minor additional changes in combination
with TNKS inhibition. A second group (II) consisting of 22 genes was moderately upregulated
by the TNKSi, more clearly upregulated by the MEKi, and additively upregulated by combined
TNKSi/MEKi treatment. The third group (group III) consisting of 7 genes was upregulated by the
MEK inhibitor, with minor additional changes in combination with TNKS inhibition. SLC2A3 (GLUT3)
gene transcription was downregulated by the TNKSi, with minor additional changes in combination
with the MEKi. Canonical pathways predicted by the Ingenuity pathway analysis (IPA) core analysis to
be regulated by group I and III is indicated in (B). With an applied cutoff at (z-score > ±2, padj < 0.01),
only the Protein Kinase A pathwa was significantly affected (highlighted). The can nical pathways
predicted by the IPA to b regulated by genes in group II is shown in (C). H atm p Scale bar (red = high,
yellow = medium and blue = low) indicates relative differences in log2 fold ch nge within e ch row.
Individual regulations in biological replicates are shown for all treatment groups.
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IPA predicted CTNNB1 (β-catenin) as the top upstream regulator of these genes (activation z-score;
−2.183, Table S3), affecting “IGF-1 signaling”, “CXCR4 signaling”, “NRF2 mediated oxidative stress
response” and “ERK/MAPK signaling” (Figure 4B). With a pre-defined cutoff (z-score >±2, padj < 0.01)
only the Protein Kinase A (PKA) pathway was significantly affected (upregulated). For the genes in
group II, the IPA software predicted TP53 (p53) as the top upstream regulator (activation z-score; 1.148,
Table S4), affecting “p53 signaling”, “D-Myoinositol (1,4,5) Trisphosphate Biosynthesis”, “Inhibition of
angiogenesis by TSP1”, and “inhibition of matrix metalloprotease” (Figure 4C). Finally, only SLC2A3
gene transcription (GLUT3 - involved in glucose transport) was mainly affected (downregulated) by
the TNKSi, with minor additional changes in combination with MEK inhibition. Together these results
show that the 50 most regulated genes were mostly influenced by the MEKi to affect both metabolic and
oxidative stress responses, as well as growth factor signaling pathways, primarily affecting molecular
and cellular functions involving cell growth, development and survival (Figure S6).
Next, we wanted to understand the underlying mechanism of the individual treatments in
relation to their effects on cell growth. The IPA software was therefore used to characterize the
canonical pathways and biological functions significantly associated with single inhibitor induced
DEG’s. At the selected dose, single TNKSi treatment induced only minor transcriptional changes in
HCT-15 cells (Figure 3A). With a mild cutoff at log fold change (lfc) > ±0.5, padj < 0.1 [data input],
z-score > ±2 (analysis output), the IPA software associated TNKSi induced DEG’s with enhanced
“cholesterol biosynthesis”, enhanced “ErbB signaling”, enhanced “glioma invasiveness signaling” and
enhanced “NFR2-mediated oxidative stress response” (Figure S7A and Tables S5 and S6). On the
other hand, MEK inhibition induced more significant transcriptional changes at the selected inhibitor
dose which the IPA software (cutoff at lfc > ±2, padj < 0.01 [data input], z-score > ±0.4 [analysis
output]) associated with reduced “ERK/MAPK signaling”, induced “PKA signaling” and induced
“osteoarthritis pathway” (Figure S7B and Table S7). Inhibited STAT3 and CTNNB1 were predicted as
the main upstream regulators of these events (Table S8). Furthermore, both TNKSi and MEKi induced
DEG’s were associated with molecular and cellular functions like cell growth and proliferation, cellular
development, and cell death and survival (Figure S7C,D).
Due to the large amount of significant DEG’s induced by combined TNKSi/MEKi treatment
(Figure 3A and Figure S8) we performed IPA analysis using a more stringent cutoff (lfc > ±2, padj < 0.01
[data input], z-score > ±2 [analysis output]), which associated these DEG’s with upregulation of
“phospholipases”, upregulation of “retinol biosynthesis”, and downregulation of “aryl hydrocarbon
receptor signaling” (Figure 5A and Table S9). These DEG’s were further predicted to affect biological
functions like cellular development, cell growth and proliferation, cell death and survival, cellular
movement, and cell cycle (Figure S9A). Inhibition of cell cycle regulators like CCND1, SRF, FOXM1 and
MYC, and upregulation of transcriptional regulators like PAX6, EHF, SMARCA4 and SMARCB1 was
predicted as main upstream regulators of these processes (Figure 5B and Table S10). However, we also
observed an enhancement (z-score = 0.378, p-value 0.012) in ERK/MAPK signaling which suggests an
induction of a feedback rescue mechanism. This is in compliance with enhanced EGFR activity previously
observed with combined TNKSi/MEKi treatment in HCT-15 cells [14], and may partly account for the
sustained cell growth (Figure 1B).
Finally, we investigated the 2528 DEG’s (Figure 3A) uniquely regulated by combined
TNKSi/MEKi treatment. According to the IPA software (lfc > ±2, padj < 0.01 [data input], z-score > ±2
[analysis output]) these genes were predicted to significantly downregulate “methionine degradation”,
downregulate “cysteine biosynthesis”, downregulate “tRNA charging”, and upregulate “cholesterol
biosynthesis” (Figure 5C and Table S11). Furthermore, these DEG’s were predicted to affect general
gene expression, DNA recombination and repair, RNA post-transcriptional modification, and cellular
assembly and organization (Figure S9B). Inhibition of POU5F1 (OCT-4), CBX5, and KLF3, and activation
of E2F6, FOXO3 and PARP9 was predicted as main upstream regulators of these processes (Figure 5D
and Table S12). Together these observations suggest that TNKSi/MEKi induced DEG’s initiate several
stress responses and rescue mechanisms in HCT-15 cells which target basic cellular functions like cell
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renewal and survival. Furthermore, predicted activation of FOXO3 and inhibition of FOXM1 provides
a positive FOXO3/FOXM1 ratio which is considered to be favorable, since these factors are crucial in
various aspects of cancer progression [28–30]. In particular, FOXO3 has been shown to both inactivate
FOXM1 at the transcriptional level and to compete for the same target genes as FOXM1 [31,32].
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core analysis (lfc > ±2, padj < 0.01 [data input], z-score > ±2 [analysis output]) was used to predict
the canonical pathways (A) and upstream regulators (B) associated with DEG’s induced by combined
TNKSi/MEKi treatment. The IPA software also predicted canonical pathways (C) and upstream regulators
(D) associated with DEG’s uniquely induced by combined TNKSi/MEKi treatment. Only predicted
upstream regulators with a measured expression log ratio are listed in (B) and (D). These analyses predict
that a positive FOXO3/FOXM1 ratio is induced by combined TNKS7/MEKi treatment (highlighted).
Inconsistency between predicted activation state and the measured transcriptional regulation may be
related to the corresponding protein activity rather than the gene transcription.
2.4. RNAseq Analysis Suggests YAP or FOXM1 Mediated Induction of Canonical WNT Signaling
Despite reduced canonical WNT signaling (Figure 2B) the growth rate of HCT-15 cells was not
affected by single TNKSi treatment (Figure 1C). A detailed evaluation of the DESeq2 and IPA analyses
revealed that TNKS inhibition downregulated transcription of canonical WNT pathway mediators like
Frizled, WNT and AXIN2 (Figures S10 and S18, and Table S13), supporting reduced canonical WNT
signaling. Additionally, TNKS inhibition induced transcription of RAS and downstream Protein kinase
B (AKT) effectors (Figures S11 and S18), which indicates initiation of a feedback rescue mechanism
through AKT to maintain normal cell growth in response to inhibition of canonical WNT signaling.
Furthermore, MEKi treatment reduced transcription of several genes involved in cell cycle
regulation (Figure S12 and Table S14), as well as enhanced transcription of RAS and ERK1/2 (Figures
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S13 and S19), which could be due to the previously reported MEKi induced activation of EGFR
in HCT-15 cells [14]. These contradictory transcriptional regulations support the mild response in
growth reduction upon MEK inhibition in HCT-15 cells. MEKi treatment also reduced transcription
of the canonical WNT inhibitor DKK1 and the transcriptional co-repressor Groucho, while enhancing
transcription of canonical WNT signaling activators like SOX and TCF/LEFs (Figures S14 and S19),
supporting enhanced canonical WNT signaling (Figure 2B). Furthermore, on the transcriptional level
we observed that MEKi induced reactivation of WNT also enhanced transcription of the canonical
WNT/YAP target genes ASCL2, BCL2L1 and BIRC5 [33–36] (Figure S15A–C), which was further
supported by enhanced transcription of several genes in the hippo/YAP signaling pathway (Figure S16).
These effects were counteracted with combined TNKSi/MEKi treatment (Figures S15A–C, S17 and S20,
and Tables S10 and S15). Single MEKi treatment also reduced transcription of the YAP target gene
FOXM1 [37], followed by reduced transcription of FOXM1 target genes, which was further reduced
with combined TNKSi/MEKi treatment (Figure S15D,E). Following reduced transcription of FOXM1
we also observed increased transcription of canonical WNT target genes like GATA6, WNT7B, SOX4
and TCF4 (Figure S15F), previously shown to be upregulated in the absence of FOXM1 [38].
These results are in agreement with the MEKi induced activation of canonical WNT activity
(Figure 2B), as well as with predicted effects of WNT mediated activation of nuclear YAP in the
intestinal crypt [39], and suggest a mechanism involving YAP and/or FOXM1. Thus, we proceeded to
investigate whether YAP and/or FOXM1 are involved in a MEKi induced rescue mechanism.
2.5. Feedback Activation of YAP is Responsible for Enhanced AXIN2 Transcription upon MEK Inhibition in
HCT-15 Cells
Previous studies have demonstrated the induction of YAP activity upon loss of the tumor
suppressor APC in colon cancer [39,40], or as a mechanism to bypass oncogenic KRAS addiction
in pancreatic cancer cells [36]. FOXM1 is one of the YAP target genes [37], and is a driver of cell
proliferation, chemo resistance and cancer progression [28]. FOXM1 has also been shown to promote
nuclear localization of β-catenin and induction of canonical WNT target gene transcription during
glioma tumorigenesis [41,42]. Based on these observations, and the above mentioned RNAseq results,
we explored whether regulation of YAP/FOXM1 signaling were responsible for the MEKi induced
elevation in canonical WNT signaling in HCT-15 cells. In addition, we also explored whether the
canonical WNT mediator β-catenin was involved.
The protein level of total YAP was unaffected by TNKS inhibition while moderately
downregulated with both single and combined MEK inhibition (Figure 6A), reflecting YAP1
transcription levels (Figure S15B,G). In contrast, YAP was strongly inactivated (P-Ser127-YAP) by TNKS
inhibition (Figure 6A), while MEKi treatment reduced inactivation of YAP compared to the DMSO
control. Combined TNKSi/MEKi treatment partially counteracted the TNKSi mediated inactivation of
YAP. Furthermore, FOXM1 protein level was slightly enhanced by TNKS inhibition, while with MEK
inhibition the FOXM1 protein level remained unaffected (Figure 6A).
To investigate whether β-catenin, YAP or FOXM1 are responsible for MEKi induced canonical
WNT signaling we performed esiRNA mediated knock down (KD) of CTNNB1, YAP1 and FOXM1
transcripts in HCT-15 cells. This resulted in 30% (β-catenin), 60% (YAP) and 60% (FOXM1) reduction
in the corresponding protein levels (Figure 6B). Next, we measured whether reduction in β-catenin,
YAP and FOXM1 proteins affected the potential of the MEKi to induce canonical WNT signaling.
Compared to their respective EGFP esiRNA controls we observed 77% (CTNNB1), 30% (YAP1) and
30% (FOXM1) reduction in STF/Renilla activity with DMSO control treatment (Figure 6C), suggesting
that all three proteins were involved in mediating canonical WNT signaling in HCT-15 cells. However,
upon MEKi treatment, STF/Renilla activity was similarly induced in both EGFP control cells (2.0 fold)
and CTNNB1 KD cells (1.9 fold) (Figure 6C). Upon YAP1 and FOXM1 KD, MEKi treatment induced
STF/Renilla activity 1.4 fold, compared to 1.6 fold in the corresponding EGFP control cells. Together,
this shows that β-catenin, YAP and FOXM1 are involved in mediating canonical WNT signaling in
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HCT-15 cells, while both YAP and FOXM1 was partially responsible for the MEKi induced canonical
WNT signaling.Cancers 2019, 11, x 10 of 19 
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Since MEK inhibition also induced AXIN2 transcription in HCT-15 cells (Figure 2B), we investigated
whether reduction in β-catenin, YAP or FOXM1 proteins affected AXIN2 transcription. Reduction in
β-catenin protein reduced transcription of AXIN2 by 49% compared to EGFP control with DMSO
treatment, while reduced YAP protein significantly enhanced transcription of AXIN2 (1.3 fold compared
to EGFP) (Figure 6D). Reduction in FOXM1 protein did not change AXIN2 transcription. Furthermore,
MEKi treatment significantly enhanced AXIN2 transcription upon EGFP control KD (1.3 fold), CTNNB1
KD (1.6 fold) and FOXM1 KD (1.3 fold). However, MEKi treatment did not alter the transcription level
of AXIN2 in YAP reduced HCT-15 cells. We therefore conclude that the MEKi induced transcription of
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AXIN2 is mediated by YAP in HCT-15 cells, although YAP also partly restrains AXIN2 transcription in
the absence of MEKi treatment.
We therefore conclude that HCT-15 cells induce canonical WNT signaling through YAP (AXIN2
transcription) and YAP/FOXM1 (STF/Renilla activity) as a feedback rescue mechanism to maintain
proliferation and survival upon MEK inhibition. Since TNKS inhibition restrains both canonical
WNT [43] and hippo/YAP [44] activity, combining MEK inhibition with TNKS inhibition disrupts the
feedback rescue mechanism induced by single agent MEK inhibition.
3. Discussion
Abnormal activation of canonical WNT signaling promotes nuclear translocation of β-catenin
and induces transcription of genes which initiate and maintain colon cancers [3,45]. In this study we
observed that MEK inhibition further induced canonical WNT signaling in APC and KRAS mutant
HCT-15 colorectal cancer cells, but not in APC mutant/KRAS WT COLO320DM cells (Figure 2).
In HCT-15 cells, MEK inhibition induced elevated β-catenin protein level, increased STF/Renilla
activity and subsequently enhanced transcription of the canonical WNT target gene AXIN2. RNAseq
analysis supported these findings showing induced transcription of typical canonical WNT target
genes upon MEK inhibition, while transcription of canonical WNT inhibitors was reduced (Figures S14,
S15F and S19). Enhanced β-catenin protein level mediated by the MEKi was initially proposed as the
obvious candidate mediating these typical canonical WNT responses. However, esiRNA mediated KD
experiments revealed that enhanced AXIN2 transcription was mediated by YAP, while both YAP and
FOXM1 partially influenced on STF/Renilla signaling (Figure 6). MEK targeted cancer therapies were
previously shown to induce YAP activity as a survival mechanism [36,46], where nuclear active YAP
promotes tumorigenesis by inducing expression of the anti-apoptotic protein BCL-xL (BCL2L1) [46].
Furthermore, YAP has also been shown to induce AXIN2 transcription in muscle fibers [47], which is
in agreement with MEKi induced AXIN2 transcription in HCT-15 cells. However, YAP has also been
observed to restrain AXIN2 transcription in mouse embryonic stem cells [39] and MCF-10 breast cancer
cells [48], which is in line with the mild induction of AXIN2 transcription in HCT-15 cells upon YAP1
KD (Figure 6D). It is therefore clear that in the absence of treatment YAP restrain AXIN2 transcription
in HCT-15 cells, while the MEKi induces AXIN2 transcription through a parallel mechanism which is
also dependent on YAP. Oppositely, TNKS inhibition reduces YAP activity in HCT-15 cells, probably
through sequestration of YAP in the β-catenin destruction complex [39], which may further explain the
attenuation of the MEKi induced WNT effects with combined TNKSi/MEKi treatment. We therefore
conclude that HCT-15 cells induce canonical WNT signaling through YAP as a feedback rescue
mechanism to maintain proliferation and survival upon MEK inhibition. Combining MEK inhibition
with TNKS inhibition is therefore an effective tool to disrupt this effect.
However, while the observed increase in STF/Renilla activity and AXIN2 transcription upon
MEK inhibition were attenuated in combination with the TNKSi, the β-catenin protein level remained
elevated compared to the DMSO control. This could be linked to the absence of AXIN1 stabilization
observed when the TNKSi was combined with the MEKi (Figure 2C). MEK inhibition has previously
been shown to reduce the level of AXIN1 protein in melanoma cells [49], although the exact mechanism
of ERK/MAPK regulation of AXIN1 needs further investigation. Reduced level of AXIN1 may
subsequently result in a compromised β-catenin destruction complex, followed by enhanced β-catenin
protein levels and nuclear accumulation of both β-catenin and YAP proteins [39].
Enhanced YAP activity upon MEK inhibition in HCT-15 cells was observed by WB analysis
(Figure 6A), as well as proposed by the RNAseq analysis through enhanced transcription of the
canonical WNT/YAP target genes ASCL2, BCL2L1 and BIRC5 (Figure S15A–C). Subsequently, the IPA
also predicted that combined TNKSi/MEKi treatment induced several stress response pathways in
HCT-15 cells, including “NRF2 mediated oxidative stress response” (Figures 4 and 5 and Figure S7),
which has been linked to resistance to oxidants and to promote aggressive proliferation of cancer
cells [50]. Previous reports have proposed a bimodal regulation between NRF2 (NFE2L2) and YAP
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where silencing of NRF2 has been shown to inhibit YAP1 transcription, while active YAP induced
transcription of FOXM1 in combination with its co-factor TEAD [37]. Finally, FOXM1 was subsequently
shown to induce NFE2L2 transcription [51]. In HCT-15 cells we observed reduced transcription of
YAP1, TEAD, FOXM1 and NFE2L2 upon MEK inhibition (Figure S15B,D,H), which were further
reduced in combination with the TNKSi. Together this proposes a connection between YAP and NRF2
mediated stress responses in HCT-15 cells (Figure 7). Furthermore, NRF2 mediated stress response has
also been shown to promote PKA signaling in cancer cells in order to mediate resistance to glucose
starvation [52]. Both PKA signaling and SLC2A3 (GLUT3) transcription were significantly regulated
upon treatment in HCT-15 cells (Figure 4).
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Figure 7. Proposed model of drug induced oxidative stress responses in HCT-15 cells. IPA generated
model of drug induced stress responses in HCT-15 cells with an overlay of DEG’s (log2 fold > 0.5,
padj < 0.1) produced by combined TNKS/MEK inhibition. Combined TNKSi/MEKi treatment promoted
a positive FOXO3/FOXM1 ratio which subsequently downregulated the NRF2 modulated antioxidative
and cryoprotective systems. Together with downregulation of canonical WNT and YAP activity the
combined TNKSi/MEKi treatment also synergistically reduced cell survival by inducing molecular
characteristics of cell cycle arrest and apoptosis. However, a feedback rescue mechanism mediated by
ERK on EGFR is proposed to maintain cell growth of the most treatment resistant cells.
Metabolic stress and increase in reactive oxygen species (ROS) have been shown to induce FOXO3
activation, enhance transcription of pro-apoptotic genes and induce differentiation [53]. RNAseq
data analysis predicted a significant change in the FOXO3/FOXM1 ratio, and highlighted both
FOXO3 (activated) and FOXM1 (inhibited) as top upstream regulators of DEG’s that are induced
with combined TNKSi/MEKi treatment (Figure 5). FOXO3 and FOXM1 are paralogs belonging to the
O subclass of the forkhead family of transcription factors, and compete for the same target genes [31,32].
However, while FOXO3 activity is thought to promote apoptosis and cell cycle arrest, FOXM1 promotes
cell proliferation, survival, DNA repair and drug resistance (reviewed by [28]). In HCT-15 cells,
reduced transcription of cell cycle mediating genes (CCND1, PCNA, CDK2, CDKN1B; Figure S15D,H,I),
and reduced transcription of anti-apoptotic genes (BMI1, BIRC5 and BCL2; Figure S15D,J), support
a cancer suppressive and favorable FOXO3/FOXM1 ratio [28] upon combined TNKSi/MEKi treatment.
Cancers 2019, 11, 164 13 of 19
This is further reflected by a synergistic growth reduction compared to single inhibitor treatments in
HCT-15 cells.
4. Materials and Methods
4.1. Cell Lines
The human colorectal cancer cell lines COLO320DM (ATCC® CCL-220™) and HCT-15 (ATCC®
CCL-225™) were grown according to the manufacturers protocol in RPMI-1640 with L-glutamine
and sodium bicarbonate medium (Sigma-Aldrich, St Louis, MO, USA, R8758), supplemented with
10% fetal bovine serum (FBS) (Gibco Products International, Big Cabin, OK, USA, 10270106), and 1%
Penicillin/Streptomycin (Pen/Strep) (Sigma-Aldrich, P4333) at 37 ◦C in a humidified atmosphere
containing 5% CO2. Cells were routinely tested for Mycoplasma using the MycoAlert Mycoplasma
detection kit (Lonza Group Ltd, Basel, Switzerland).
4.2. Inhibitors
Inhibitors were dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich, 0.02%), which was also
used as vehicle control. The following inhibitors were used: G007-LK (ChemRoyal Inc., Atlanta, GA,
USA, 1 µM), GDC-0973 (MedChem Express, Sollentuna Sweden, 1 µM) and GDC-0623 (MedChem
Express, 1 µM).
4.3. Proliferation Analysis
A total of 1000 COLO320DM and HCT-15 cells were plated in six parallels per treatment in
a 96-well plate (NuncTM,Thermo Fischer Scientific, Boston, MA, USA). The following day, culture
media was replaced with vehicle or inhibitor containing media. Cell confluence was quantified with
the IncuCyte live-cell analysis system (Essen BioScience, Ann Arbor, MI, USA). Images were captured
every second hour to monitor proliferation and results were retrieved through corresponding IncuCyte
2011A software (Essen BioScience), and exported to Excel for further analysis and graph design.
4.4. SuperTopFlash (STF) Assay
The COLO320DM-STF and HCT-15-STF cell lines have been described previously [43]. A total
of 15,000 cells were plated per well in a 96-well plate (NuncTM). The following day, culture media
was replaced with vehicle or inhibitor containing media. After 24 h of treatment luciferase activity
was measured using the Dual-Luciferase Reporter Assay 1000 kit (Promega, Fitchburg, WI, USA)
according to the manufacturer’s protocol, and with the GloMax®-Multi Detection System (Promega).
Results were retrieved through corresponding GloMax®-Multi + Detection System InstinctTM Software
(Promega), and exported to Excel for further analysis and graph design. All STF Assays were performed
with at least 3 biological replicates, each with at least 3 technical replicates.
4.5. RNA Extraction and Quantitative Real Time PCR (RT-qPCR)
Total RNA was isolated after 24 h of treatment using a GenEluteTM Mammalian Total RNA
Miniprep Kit (Sigma Aldrich) following the manufacturer’s instructions. cDNA was synthesized from
1 µg total RNA using a SuperScript®VILO cDNA synthesis Kit (Life Technologies, Carlsbad, CA,
USA) following the manufacturer’s instructions. Prior to RNA sequencing, samples were treated with
DNaseI according to manufacturer’s instructions (Sigma Aldrich). RT-qPCR was carried out using
a TaqMan Gene expression Mastermix (Life Technologies, 4369510) and ViiA7 (Applied Biosystems,
Foster City, CA, USA). The amplification protocol was initiated with 2 min at 50 ◦C followed by
denaturation for 10 min at 95 ◦C, then 40 cycles with denaturation for 15 s at 95 ◦C, annealing of
TaqMan probes and amplification at 60 ◦C for 1 min. All RT-qPCR analyses were performed with 3
biological replicates, each with 3 technical replicates. Gene expressions are normalized to the GAPDH
internal control, and bars indicate fold change relative to DMSO control.
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The following probes were used (all from Life Technologies): AXIN2; Hs00610344_m1, 4351370.
CCND1; Hs00765553_m1, 4331182.CTNNB1; Hs00991810_g1, 4351372. FOXM1; Hs01073586_m1,
4453320. SP5; Hs01370227_mH, 4453320. ASCL2; Hs00270888_s1, 4351370. BIRC5; Hs04194392_s1,
4448892. TCF7L2; Hs01009044_m1, 4448892. CDH1; Hs01023894_m1, 4453320. FOXO3; Hs04195365_s1,
4448892. FOSL1; Hs04187685_m1, 4448892. FOS; Hs01119266_g1, 4448892. YAP1; Hs00371735_m1,
4453320. GAPDH; Hs02758991_g1, 4351368.
4.6. esiRNA Mediated Knock Down
800,000 HCT-15 cells were plated per well in a 6-well dish. The following day the culture media
was exchanged with media without antibiotics and transfected with either 50 nM EGFP esiRNA
(EHUEGFP, Sigma-Aldrich,), 50 nM CTNNB1 (EHU139421, Sigma-Aldrich), 50 nM YAP1 (EHU113021,
Sigma-Aldrich) or 50 nM FOXM1 esiRNA (EHU124431, Sigma-Aldrich), using Lipofectamine
RNAiMax Transfection Reagent (ThermoFisher, Boston, MA, USA, 13778075). The following day
15,000 cells were seeded in 96-well plates for luciferase assay, 150,000 cells were seeded in 12-well
plates for RNA isolation, and 400,000 cells in 6-well plates for protein analysis. Total protein extracts
were monitored for β-catenin, YAP and FOXM1 reduction 72 h post transfection. All esiRNA analyses
were performed with three biological replicates.
4.7. RNA Sequencing
Total RNA was isolated using GenEluteTM Mammalian Total RNA Miniprep Kit (Sigma Aldrich),
followed by DNaseI (Sigma Aldrich) treatment for 15 min, according to the manufacturer’s instructions.
Sequencing libraries were generated from three biological replicates of cultured HCT-15 cells treated
with DMSO (0.02%), G007-LK (1 µM), GDC-0973 (1 µM) or G007-LK and GDC-0973 for 24 h using the
Illumina TruSeq stranded mRNA kit (Illumina Inc., San Diego CA, USA). The libraries were subsequently
sequenced on the HiSeq2500 (Illumina Inc.) at the Genomics Core Facility Oslo (Oslo University Hospital,
Norway). Reads were aligned using STAr aligner 2.5.0 (https://github.com/alexdobin/STAR) and
counts generated using cufflinks 2.2.1. (http://cole-trapnell-lab.github.io/cufflinks/).
Differentially expressed genes (DEG’s) for the treatment effects were identified based on the
counts, using the DESeq2 package in the R programming environment [54,55] (The R Project for
Statistical Computing). The scripts used to process and analyze the data, and create the related figures
and tables, are found in supplementary methods (Supplementary materials and methods DESeq2).
DEG’s for each treatment effect with an absolute log2-fold change of > 0.5 and an adjusted p-value
of < 0.1 were compared using a Venn diagram. Pheatmap was used to generate heatmaps in R [56].
Expression data including log2-fold change and adjusted p-values (method), from the treatment
comparisons (G007-LKvsDMSO, GDC-0973vsDMSO and G007-LK/GDC-0973vsDMSO) as well as
a list of 2525 genes unique to G007-LK/GDC-0973vsDMSO, were uploaded into Ingenuity Pathway
Analysis (IPA) version 01-10 (Qiagen, Redwood City, CA, USA). The expression data, with an absolute
log2 fold value of >0.3, >1 or >2, and an adjusted p-value of < 0.1 was analyzed using the core analysis
function with the Ingenuity Knowledge Base (genes only) reference set and direct relationships, with no
filters set for node types, data sources, confidence, species, tissues & cell lines and mutations. Data for
predicted canonical pathways and upstream regulators were used with a z-score cutoff of > ±0.4
(GDC-0973vsDMSO) or > ±2 (G007-LK/GDC-0973vsDMSO and G007-LK/GDC-0973 unique).
4.8. Western Blot Protein Analysis
Cells were lysed in either RIPA buffer (Millipore, Burlington, MA, USA) for total protein extracts or
with NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher,) for nuclear and cytoplasmic
protein fractions after 24 h of treatment with inhibitors or vehicle control. Equal amounts of protein
(15–20 µg) were denatured, separated on SDS-PAGE gels (Bio-Rad Laboratories, Hercules, CA, USA)
and transferred to polyvinylidene-difluoride-membranes (Millipore). After blocking in 5% skim milk
(AppliChem)/TBS-T for 30 min, membranes were probed with primary antibody in TBS-T over night
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at 4 ◦C. Following secondary antibody incubation, proteins were visualized with chemiluminescent
substrate (ECL prime Western Blotting Detection Reagent, Sigma-Aldrich). The following primary
antibodies were used: AXIN1 (Cell Signalling Technology, Danvers, MA, USA, [CS]#2087), non-phospho
(active)-β-catenin (CS#8814), YAP (Santa Cruz Biotechnology, Santa Cruz CA, USA, sc-101199), P-YAP
(ser127) (CS#4911), FOXM1 (Santa Cruz Biotechnology, sc-271746), total β-catenin (BD Transduction
Laboratories, BD Biosciences, CA, USA, 610153), Tankyrase 1/2 (E10) (Santa Cruz Biotechnology,
sc-365897), MEK1/2 (CS#9122), P-MEK1/2 (ser217/221) (CS#9121), GAPDH (Santa Cruz Biotechnology,
sc-32233), LAMIN B1 (ab16048-100, Abcam,), ACTIN (A2066, Sigma). Primary antibodies were visualized
with secondary IgG-HRP conjugated antibodies (715-035-150 [mouse] or 711-035-152 [rabbit], Jackson
ImmunoResearch, West Grove, PA, USA) and enhanced with chemiluminescent substrate (ECL prime
Western Blotting Detection Reagent, Sigma-Aldrich, RPN2236). Figures show representative data.
ACTIN, GAPDH or LAMINB1 documents equal protein loading. Loading controls were always run on
the same blot used for the experimental samples.
4.9. Statistical Analysis
All statistical analyses were performed in Excel. For comparisons of two groups, equal variances
within the datasets were first analyzed using F-Test. When the F-Test passed (p ≥ 0.05), a 2-tailed type
2 Student’s t-test was performed. If the F-Test failed (p ≤ 0.05), a 2-tailed type 3 Student’s t-test was
applied. When performing Students t-test, p < 0.05 was regarded as a statistically significant difference.
5. Conclusions
Together these results suggest that combined TNKS/MEK inhibition induces metabolic and
oxidative stress responses in HCT-15 cells which promote a positive FOXO3/FOXM1 ratio that
synergistically reduces cell growth through molecular characteristics of cell cycle arrest and apoptosis.
However, although TNKS inhibition counteracts the MEKi induced feedback rescue mechanism
through YAP, cell growth was not entirely eradicated, proposing further rescue mechanisms to maintain
cell growth. MEK inhibition has previously been shown to suppress a negative feedback mediated by
ERK on HER2/EGFR [57], which is supported by induced activation of EGFR upon MEK inhibition
in HCT-15 cells [14], and suggests the need for further inhibitor treatments to overcome rescue
mechanisms in this APC and KRAS mutated cell line.
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